Michael Specter puts the latest outbreak in perspective:
Ebola is truly deadly, but the many lurid headlines predicting a global pandemic miss a central point. In its epidemic reach, Ebola is often compared with H.I.V. But they are nothing alike. H.I.V. has killed at least thirty million people, mostly by spreading quietly, burrowing into the cells it infects, and then, at times, lurking for years before destroying the immune system of its host. Ebola’s incubation period is between two and twenty-one days long. The virus kills rapidly. There is nothing insidious about it.
Ebola won’t kill us all, but something else might. Like everything living on Earth, viruses must evolve to survive. That is why avian influenza has provoked so much anxiety; it has not yet mutated into an infection that can spread easily. Maybe it never will, but it could happen tomorrow. A pandemic is like an earthquake that we expect but cannot quite predict. As [Spillover author David] Quammen puts it, every emerging virus “is like a sweepstakes ticket, bought by the pathogen, for the prize of a new and more grandiose existence. It’s a long-shot chance to transcend the dead end. To go where it hasn’t gone and be what it hasn’t been. Sometimes the bettor wins big.”
He’s right, of course, and it is long past time to develop a system that can easily monitor that process. If we don’t, the next pandemic could make Ebola look weak.
Three experts in disease control combat bad reporting on Ebola:
The desire of the international media to attract viewers has led some careless journalists to focus almost exclusively on the fear-invoking mode of death from the disease. While it may increase their ratings, it lets the real culprits off the hook. Limited health infrastructure, insufficient numbers of trained health workers, too few fully equipped labs, and not enough education and preventative epidemiology are the sad realities that push this scourge on. The image of a victim coughing up blood creates stigma instead of engaging international viewers with the true and preventable human tragedy in these communities. It also distracts from one of the more disturbing facts associated with this outbreak, which is how wealthy communities feel content to live in a world where society spends more on eliminating wrinkles than with basic health infrastructure that could, among many other things, help quench an outbreak like the one we’re currently experience in West Africa.
Kliff covers attempts to create a vaccine:
[Professor Daniel] Bausch says that the obstacle to developing an Ebola vaccine isn’t the science; researchers have actually made really great strides in figuring out how to fight back against Ebola and the Marburg virus, a similar disease.
“We now have a couple of different vaccine platforms that have shown to be protective with non-human primates,” says Bausch, who has received awards for his work containing disease outbreaks in Uganda. He is currently stationed in Lima, Peru, as the director of the emerging infections department of Naval Medical Research Unit 6.
The problem, instead, is the economics of drug development. Pharmaceutical companies have little incentive to pour research and development dollars into curing a disease that surfaces sporadically in low-income, African countries. They aren’t likely to see a large pay-off at the end — and could stand to lose money.
The Dish 